Events Partner Content J+D Forecasting bring their Oncology Forecasting Training to... Oncology Forecasting Training In Boston by J+D Forecast
News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal... Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the
News MSD takes a $400m bite of SciBrunch's KRAS drug MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
